{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:12:46Z","timestamp":1769634766850,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Increased survival and life expectancy among patients with prostate cancer results in\u00a0an increased risk of developing a second primary cancer (SPC). We aimed to describe the occurrence of SPCs in a population-based cohort with a prostate first primary cancer (FPC), in Northern Portugal. A cohort of 13,222 patients with a prostate FPC from the North Region Cancer Registry of Portugal, diagnosed between 2000 and 2009, was followed until 31 December 2021, for synchronous (within six months of FPC diagnosis) and metachronous SPCs (all others). We describe absolute and relative frequencies of SPCs, incidence rates and standardized incidence ratios of SPCs (compared to the male general population), and cumulative incidence of metachronous SPCs. A total of 1953 (14.8%) patients with a prostate FPC developed an SPC, mostly of the colon, lung and bladder;\u00a0synchronous SPCs occurred mainly in the bladder. Compared to the general male population, patients with a prostate FPC had a globally lower incidence of all cancers, and lung and oesophagus cancers, but a\u00a0higher incidence of bladder and pancreas cancers. Overall, the incidence of synchronous SPCs was also significantly higher, likely reflecting the incidental diagnosis of SPCs. The 20-year cumulative incidence of metachronous SPCs was 15.4%. Patients with a prostate FPC had a\u00a0lower overall incidence of SPCs than the general male population, despite a\u00a0higher incidence in the first six-months after the SPC diagnosis. After that period, one out of seven may be expected to develop an SPC within two decades. Continued cancer surveillance among survivors is needed.<\/jats:p>","DOI":"10.1007\/s10238-025-01654-7","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:39:04Z","timestamp":1745231944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Second primary cancers among males with a first primary prostate cancer: a population-based study in Northern Portugal"],"prefix":"10.1007","volume":"25","author":[{"given":"Jos\u00e9","family":"Taveira-Barbosa","sequence":"first","affiliation":[]},{"given":"Samantha","family":"Morais","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Garcia","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"Bento","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Lunet","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"3","key":"1654_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA: A Cancer J Clin"},{"issue":"6","key":"1654_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA: A Cancer J Clin"},{"issue":"1","key":"1654_CR3","first-page":"12","volume":"74","author":"C Siegel","year":"2024","unstructured":"Siegel C, Giaquinto A, Jemal A. Cancer statistics. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1654_CR4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.eururo.2007.07.002","volume":"52","author":"PJ Bostrom","year":"2007","unstructured":"Bostrom PJ, Soloway MS. Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk? Eur Urol. 2007;52(4):973\u201382.","journal-title":"Eur Urol"},{"key":"1654_CR5","unstructured":"Cancer Facts & Figures 2012. American Cancer Society. 2011."},{"issue":"17","key":"1654_CR6","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1002\/cncr.28769","volume":"120","author":"EJ Davis","year":"2014","unstructured":"Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA. Risk of second primary tumors in men diagnosed with prostate cancer: A population-based cohort study. Cancer. 2014;120(17):2735\u201341.","journal-title":"Cancer"},{"issue":"4","key":"1654_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","volume":"12","author":"AB de Gonzalez","year":"2011","unstructured":"de Gonzalez AB, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12(4):353\u201360.","journal-title":"Lancet Oncol"},{"key":"1654_CR8","unstructured":"RON. Registo Oncol\u00f3gico Nacional de Todos os Tumores na Popula\u00e7\u00e3o Residente em Portugal, em 2021. Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil - EPE, ed. Porto, 2024."},{"issue":"5","key":"1654_CR9","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386.","journal-title":"Int J Cancer"},{"key":"1654_CR10","unstructured":"World Health Organization.\u00a0International classification of diseases for oncology (ICD-O), 3rd ed., 1st revision.\u00a0World Health Organization. 2013."},{"key":"1654_CR11","unstructured":"World Health Organization.\u00a0The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines.\u00a0World Health Organization. 1992."},{"key":"1654_CR12","doi-asserted-by":"crossref","unstructured":"International rules for multiple primary cancers (ICD-0 third edition). European Journal of Cancer Prevention. 2005; 14(4):307\u20138.","DOI":"10.1097\/00008469-200508000-00002"},{"key":"1654_CR13","unstructured":"Ferretti S, Giacomin A. Cancer Registration Handbook 2010. AIRTUM (Associazione Italiana Registri Tumori). 2010."},{"key":"1654_CR14","unstructured":"Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. John Wiley & Sons; 2011."},{"key":"1654_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"1654_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2340\/1651-226X.2024.24334","volume":"63","author":"MC Jahrei\u00df","year":"2024","unstructured":"Jahrei\u00df MC, Incrocci L, Aben KKH, et al. The impact of baseline health factors on second primary cancer risk after radiotherapy for prostate cancer. Acta Oncol. 2024;63:511\u20137.","journal-title":"Acta Oncol"},{"issue":"11","key":"1654_CR17","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1002\/cam4.1764","volume":"7","author":"S Chattopadhyay","year":"2018","unstructured":"Chattopadhyay S, Zheng G, Hemminki O, F\u00f6rsti A, Sundquist K, Hemminki K. Prostate cancer survivors: Risk and mortality in second primary cancers. Cancer Med. 2018;7(11):5752\u20139.","journal-title":"Cancer Med"},{"issue":"7","key":"1654_CR18","doi-asserted-by":"publisher","first-page":"e102596","DOI":"10.1371\/journal.pone.0102596","volume":"9","author":"M Van Hemelrijck","year":"2014","unstructured":"Van Hemelrijck M, Feller A, Garmo H, et al. Incidence of second malignancies for prostate cancer. PLoS ONE. 2014;9(7):e102596\u2013606.","journal-title":"PLoS ONE"},{"issue":"10","key":"1654_CR19","doi-asserted-by":"publisher","first-page":"e0140693","DOI":"10.1371\/journal.pone.0140693","volume":"10","author":"JY Joung","year":"2015","unstructured":"Joung JY, Lim J, Oh CM, et al. Risk of second primary cancer among prostate cancer patients in Korea: a population-based cohort study. PLoS ONE. 2015;10(10):e0140693-e140703.","journal-title":"PLoS ONE"},{"issue":"1","key":"1654_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S1470-2045(23)00538-7","volume":"25","author":"TK Kjaer","year":"2024","unstructured":"Kjaer TK, Andersen EAW, Ursin G, et al. Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study. Lancet Oncol. 2024;25(1):126\u201336.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1654_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2013.09.012","volume":"40","author":"KC Oeffinger","year":"2013","unstructured":"Oeffinger KC, Baxi SS, Novetsky Friedman D, Moskowitz CS. Solid tumor second primary neoplasms: who is at risk, what can we do? Semin Oncol. 2013;40(6):676\u201389.","journal-title":"Semin Oncol"},{"issue":"16","key":"1654_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006675","volume":"96","author":"Y Liu","year":"2017","unstructured":"Liu Y, Dong C, Chen L. The clinicopathological features of second primary cancer in patients with prior breast cancer. Medicine (Baltimore). 2017;96(16): e6675.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1654_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/CEJ.0b013e3282f75ee5","volume":"17","author":"L S\u00e1nchez","year":"2008","unstructured":"S\u00e1nchez L, Lana A, Hidalgo A, et al. Risk factors for second primary tumours in breast cancer survivors. Eur J Cancer Prev. 2008;17(5):406\u201313.","journal-title":"Eur J Cancer Prev"},{"issue":"2","key":"1654_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.radonc.2013.12.012","volume":"110","author":"L Murray","year":"2014","unstructured":"Murray L, Henry A, Hoskin P, Siebert F-A, Venselaar J. Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiother Oncol. 2014;110(2):213\u201328. https:\/\/doi.org\/10.1016\/j.radonc.2013.12.012.","journal-title":"Radiother Oncol"},{"key":"1654_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.771956","volume":"11","author":"MC Jahrei\u00df","year":"2021","unstructured":"Jahrei\u00df MC, Heemsbergen WD, van Santvoort B, et al. Impact of advanced radiotherapy on second primary cancer risk in prostate cancer survivors: a nationwide cohort study. Front Oncol. 2021;11: 771956.","journal-title":"Front Oncol"},{"issue":"3","key":"1654_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000356115","volume":"93","author":"T Jin","year":"2014","unstructured":"Jin T, Song T, Deng S, Wang K. Radiation-induced secondary malignancy in prostate cancer: a systematic review and meta-analysis. Urol Int. 2014;93(3):279\u201388.","journal-title":"Urol Int"},{"key":"1654_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i851","volume":"352","author":"CJ Wallis","year":"2016","unstructured":"Wallis CJ, Mahar AL, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016;352: i851.","journal-title":"BMJ"},{"key":"1654_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.796907","volume":"11","author":"S Wang","year":"2022","unstructured":"Wang S, Tang W, Luo H, Jin F, Wang Y. Efficacy and toxicity of whole pelvic radiotherapy versus prostate-only radiotherapy in localized prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;11: 796907.","journal-title":"Front Oncol"},{"issue":"3","key":"1654_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/CEJ.0000000000000539","volume":"29","author":"R Braga","year":"2020","unstructured":"Braga R, Costa AR, Pina F, Moura-Ferreira P, Lunet N. Prostate cancer screening in Portugal: prevalence and perception of potential benefits and adverse effects. Eur J Cancer Prev. 2020;29(3):248\u201351.","journal-title":"Eur J Cancer Prev"},{"key":"1654_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.18332\/tid\/157231","volume":"21","author":"S Al-Fayez","year":"2023","unstructured":"Al-Fayez S, El-Metwally A. Cigarette smoking and prostate cancer: a systematic review and meta-analysis of prospective cohort studies. Tob Induc Dis. 2023;21:19.","journal-title":"Tob Induc Dis"},{"issue":"5","key":"1654_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.eururo.2022.03.033","volume":"83","author":"SHJ Jochems","year":"2023","unstructured":"Jochems SHJ, Fritz J, H\u00e4ggstr\u00f6m C, J\u00e4rvholm B, Stattin P, Stocks T. Smoking and risk of prostate cancer and prostate cancer death: a pooled study. Eur Urol. 2023;83(5):422\u201331.","journal-title":"Eur Urol"},{"issue":"4","key":"1654_CR32","first-page":"272","volume":"64","author":"M Karam-Hage","year":"2014","unstructured":"Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: an overview for clinicians. CA Cancer J Clin. 2014;64(4):272\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1654_CR33","doi-asserted-by":"publisher","first-page":"9956","DOI":"10.3390\/curroncol29120782","volume":"29","author":"S Chellappan","year":"2022","unstructured":"Chellappan S. Smoking cessation after cancer diagnosis and enhanced therapy response: mechanisms and significance. Curr Oncol. 2022;29(12):9956\u201369.","journal-title":"Curr Oncol"},{"issue":"3","key":"1654_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10238-018-0498-1","volume":"18","author":"A Romaszko-Wojtowicz","year":"2018","unstructured":"Romaszko-Wojtowicz A, Buci\u0144ski A, Doboszy\u0144ska A. Impact of smoking on multiple primary cancers survival: a retrospective analysis. Clin Exp Med. 2018;18(3):391\u20137.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1654_CR35","doi-asserted-by":"publisher","first-page":"20083","DOI":"10.1038\/s41598-023-45856-z","volume":"13","author":"T Tiruye","year":"2023","unstructured":"Tiruye T, David R, O\u2019Callaghan M, et al. Risk of secondary malignancy following radiation therapy for prostate cancer. Sci Rep. 2023;13(1):20083.","journal-title":"Sci Rep"},{"key":"1654_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canep.2017.10.004","volume":"51","author":"J J\u00e9gu","year":"2017","unstructured":"J\u00e9gu J, Moitry M, Bara S, et al. Methodological issues of assessing the risk of a second cancer occurring in the same site as a first cancer using registry data. Cancer Epidemiol. 2017;51:41\u20133.","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"1654_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.oraloncology.2015.01.010","volume":"51","author":"J J\u00e9gu","year":"2015","unstructured":"J\u00e9gu J, Belot A, Borel C, et al. Effect of previous history of cancer on survival of patients with a second cancer of the head and neck. Oral Oncol. 2015;51(5):457\u201363.","journal-title":"Oral Oncol"},{"issue":"2","key":"1654_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","volume":"2","author":"A Vogt","year":"2017","unstructured":"Vogt A, Schmid S, Heinimann K, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017;2(2): e000172.","journal-title":"ESMO Open"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01654-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01654-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01654-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:46:03Z","timestamp":1764917163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01654-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1654"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01654-7","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of the Portuguese Institute of Oncology of Porto (Ref. CES IPO: 50\/2019) and the analyses were performed according to RORENO guidelines ensuring the anonymity of information used. The study was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"122"}}